News
-
-
-
COMMUNIQUÉ DE PRESSE
Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2025
Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2025, notamment sur les avancées de son vaccin thérapeutique TG4050 contre le cancer de la tête et du cou -
-
-
-
COMMUNIQUÉ DE PRESSE
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's BT-001 oncolytic virus in combination with pembrolizumab shows positive antitumoral activity in refractory tumors. Exciting clinical data presented at ESMO 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Transgene to participate in upcoming meetings with biotech industry leaders to discuss positive clinical data on neoantigen cancer vaccine TG4050 and present innovative immunotherapies. Learn more at www.transgene.com
